ACADIA Pharmaceuticals Inc (ACAD)
15.25
+0.04
(+0.26%)
USD |
NASDAQ |
May 10, 16:00
15.25
0.00 (0.00%)
After-Hours: 20:00
ACADIA Pharmaceuticals Net Income (TTM): -1.71M for March 31, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -1.71M |
| December 31, 2023 | -61.29M |
| September 30, 2023 | -148.81M |
| June 30, 2023 | -110.82M |
| March 31, 2023 | -145.94M |
| December 31, 2022 | -215.98M |
| September 30, 2022 | -217.34M |
| June 30, 2022 | -204.62M |
| March 31, 2022 | -214.48M |
| December 31, 2021 | -167.87M |
| September 30, 2021 | -191.54M |
| June 30, 2021 | -261.74M |
| March 31, 2021 | -260.01M |
| December 31, 2020 | -281.58M |
| September 30, 2020 | -267.86M |
| June 30, 2020 | -225.18M |
| March 31, 2020 | -237.98M |
| December 31, 2019 | -235.26M |
| September 30, 2019 | -247.72M |
| June 30, 2019 | -267.88M |
| March 31, 2019 | -276.20M |
| December 31, 2018 | -245.19M |
| September 30, 2018 | -248.57M |
| June 30, 2018 | -251.68M |
| March 31, 2018 | -255.86M |
| Date | Value |
|---|---|
| December 31, 2017 | -289.40M |
| September 30, 2017 | -299.23M |
| June 30, 2017 | -305.59M |
| March 31, 2017 | -309.47M |
| December 31, 2016 | -271.39M |
| September 30, 2016 | -238.48M |
| June 30, 2016 | -205.77M |
| March 31, 2016 | -173.83M |
| December 31, 2015 | -164.44M |
| September 30, 2015 | -147.02M |
| June 30, 2015 | -132.90M |
| March 31, 2015 | -115.02M |
| December 31, 2014 | -92.48M |
| September 30, 2014 | -76.16M |
| June 30, 2014 | -62.07M |
| March 31, 2014 | -49.65M |
| December 31, 2013 | -37.95M |
| September 30, 2013 | -32.71M |
| June 30, 2013 | -24.42M |
| March 31, 2013 | -20.75M |
| December 31, 2012 | -20.85M |
| September 30, 2012 | -19.34M |
| June 30, 2012 | -22.01M |
| March 31, 2012 | -23.15M |
| December 31, 2011 | -22.76M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-281.58M
Minimum
Dec 2020
-1.71M
Maximum
Mar 2024
-198.28M
Average
-216.66M
Median
Net Income (TTM) Benchmarks
| Amylyx Pharmaceuticals Inc | 49.27M |
| Regulus Therapeutics Inc | -30.04M |
| Minerva Neurosciences Inc | -31.60M |
| Viking Therapeutics Inc | -93.72M |
| CytomX Therapeutics Inc | -0.569M |